title: Improvement of diabetic retinopathy with intravitreal Ranibizumab.
abstract: This study indicates that in addition to the significant improvement in visual acuity and reduction of central retinal thickness in patients with center-involving diabetic macular edema, intravitreal anti-VEGF treatment with Ranibizumab may also lead to a significant stabilization or even improvement of diabetic retinopathy.
authors: Department of Ophthalmology, Ludwig-Maximilians-Universiy, Munich, Germany. marcus.kernt@med.uni-muenchen.de
authors: Marcus
authors: M
authors: Kernt
authors: Sarah
authors: S
authors: Cserhati
authors: Florian
authors: F
authors: Seidensticker
authors: Raffael
authors: R
authors: Liegl
authors: Anselm
authors: A
authors: Kampik
authors: Aljoscha
authors: A
authors: Neubauer
authors: Michael W
authors: MW
authors: Ulbig
authors: Lukas
authors: L
authors: Reznicek
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab